The oncologist
-
On May 19, 2004, azacitidine (5-azacytidine; Vidaza(trade mark); Pharmion Corporation, Boulder, CO, http://www.pharmion.com) for injectable suspension received regular approval by the U. S. Food and Drug Administration (FDA) for the treatment of all subtypes of myelodysplastic syndrome (MDS). ⋯ Azacitidine, the first drug approved by the U. S. FDA for MDS, has a favorable safety profile and provides a clinical benefit of eliminating transfusion dependence and complete or partial normalization of blood counts and bone marrow blast percentages in responding patients.